Chemomab Therapeutics’ (CMMB) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer restated their outperform rating on shares of Chemomab Therapeutics (NASDAQ:CMMB) in a research note published on Friday,Benzinga reports. Oppenheimer currently has a $11.00 price objective on the stock, down from their previous price objective of $13.00.

Chemomab Therapeutics Stock Down 3.7 %

Chemomab Therapeutics stock opened at $1.68 on Friday. The stock has a market capitalization of $24.05 million, a PE ratio of -1.68 and a beta of 0.53. The company has a 50 day moving average of $1.56 and a 200-day moving average of $1.28. Chemomab Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.55.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period last year, the company earned ($0.72) EPS. Equities analysts anticipate that Chemomab Therapeutics will post -0.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).